Ritchie Craig W, Molinuevo José Luis, Truyen Luc, Satlin Andrew, Van der Geyten Serge, Lovestone Simon
Centre for Clinical Brain Sciences, Department of Psychiatry, University of Edinburgh, Edinburgh, UK.
BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.
Lancet Psychiatry. 2016 Feb;3(2):179-86. doi: 10.1016/S2215-0366(15)00454-X. Epub 2015 Dec 10.
Alzheimer's dementia affects more than 40 million people worldwide with substantial increases in prevalence anticipated. Interventions that either modify risk or reduce the development of early disease could delay the onset of dementia or reduce the rate of cognitive and functional decline. The European Prevention of Alzheimer's Dementia (EPAD) is a public-private consortium, funded by the Innovative Medicines Initiative, designed to increase the likelihood of successful development of new treatments for the secondary prevention of Alzheimer's dementia. EPAD will help with testing of different agents in this pre-dementia population through four components: improvement of access to existing cohorts and registries, development of the EPAD Registry of approximately 24,000 people who might be at increased risk of developing Alzheimer's dementia, establishment of the EPAD Longitudinal Cohort Study of 6000 people at any one time, and establishment of an adaptive, proof-of-concept trial including 1500 participants at any given time. The need for EPAD and its key design elements are described, and we discuss EPAD in relation to similar projects in progress. These parallel efforts reflect the need for a coordinated, worldwide battle against dementia, in which EPAD will play a crucial role.
全球有超过4000万人受阿尔茨海默病性痴呆影响，预计患病率还将大幅上升。改变风险或减缓早期疾病发展的干预措施可能会推迟痴呆症的发病，或降低认知和功能衰退的速度。欧洲预防阿尔茨海默病性痴呆（EPAD）是一个公私合营的联盟，由创新药物计划资助，旨在提高成功开发阿尔茨海默病性痴呆二级预防新疗法的可能性。EPAD将通过四个部分帮助在痴呆前期人群中测试不同药物：改善对现有队列和登记处的利用，建立约24000名可能患阿尔茨海默病性痴呆风险增加人群的EPAD登记处，随时建立6000人的EPAD纵向队列研究，以及随时建立一个包括1500名参与者的适应性概念验证试验。介绍了EPAD的必要性及其关键设计要素，并讨论了EPAD与正在进行的类似项目的关系。这些并行的努力反映了全球协同对抗痴呆症的必要性，其中EPAD将发挥关键作用。
